CSPC Pharma was already on track for a tough earnings season after its nine-month profits fell 15.9% Another blow was the sudden departure of the firm's head of innovative drug research, Liu ...

BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License ...

CSPC is one of the largest and oldest pharmaceutical companies in China. Anchored by its nervous system business segment due to its flagship drug NBP, CSPC has a portfolio of innovative and ...

CSPC operates in a fast-growing and rapidly changing environment. Like most healthcare sectors in China, drug manufacturing has grown faster than GDP, and is projected to continue this trend over ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying (PDF) China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate (ADC ...

Madrid, Spain - February 17, 2025 The designer Modesto Lomba appeals to the pause with his new collection 'Hall', which alludes to the space where it has been held in the Marriot Hotel in Madrid ...

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

CSPC Megalith Biopharmaceutical has entered into a license agreement with Radiance Biopharma (9993: HK) for the development and commercialization of SYS6005, a recombinant anti-human receptor tyrosine ...